Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    366 result(s) found for: Vaccine therapy. Displaying page 4 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005427-36 Sponsor Protocol Number: NL75654.078.20 Start Date*: 2021-05-26
    Sponsor Name:Erasmus MC Cancer Center [...]
    1. Erasmus MC Cancer Center
    2. Erasmus MC Cancer Center
    Full Title: A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthet...
    Medical condition: non small cell lung cancer (NSCLC)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002502-75 Sponsor Protocol Number: P-pVAC-SARS-CoV-2 Start Date*: 2020-11-26
    Sponsor Name:University Hospital Tuebingen
    Full Title: P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults
    Medical condition: healthy subjects obtaining a potential vaccine for COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003573-28 Sponsor Protocol Number: V87_26 Start Date*: 2014-02-06
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase III Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elde...
    Medical condition: Pandemic Influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000509-26 Sponsor Protocol Number: ANRS0002S Start Date*: 2021-02-24
    Sponsor Name:Inserm-ANRS
    Full Title: A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) an...
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004125-23 Sponsor Protocol Number: CCRG19-002 Start Date*: 2021-05-10
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma
    Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004124-42 Sponsor Protocol Number: CCRG19-001 Start Date*: 2023-04-18
    Sponsor Name:Antwerp University Hopsital
    Full Title: First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients
    Medical condition: histologically or cytologically confirmed solid tumor of the pancreas, esophagus, liver or ovaries that is advanced, recurrent or progressing after at least first-line anti-cancer treatment, or fo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003710-39 Sponsor Protocol Number: IJB-COVID-001 Start Date*: 2021-11-09
    Sponsor Name:INSTITUT JULES BORDET
    Full Title: COVID-19 : Immune response in patients with cancer undergoing vaccination against SARS-CoV-2
    Medical condition: adult cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004527-23 Sponsor Protocol Number: MM1636 Start Date*: 2017-03-14
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017809-11 Sponsor Protocol Number: 112673 Start Date*: 2010-09-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/IIa randomized, observer-blind, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals’ herpes zoster vaccine, gE/AS01B in comparison to pl...
    Medical condition: Vaccination against herpes zoster (HZ) in adult HIV-infected subjects.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004822-85 Sponsor Protocol Number: ABCSG-34 Start Date*: 2012-01-05
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer
    Medical condition: primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000850-36 Sponsor Protocol Number: 201600136 Start Date*: 2017-05-01
    Sponsor Name:Archivel Farma S.L.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos...
    Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004869-14 Sponsor Protocol Number: CLL19H1 Start Date*: 2019-04-15
    Sponsor Name:Dept. of hematology, Herlev Hospital
    Full Title: Peptide vaccination with PD-L1 and PD-L2 peptides in untreated chronic lymphatic leukemia.
    Medical condition: Chronic lymphocytic leukemia with un-mutated IGHV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003990-93 Sponsor Protocol Number: MY18H2 Start Date*: 2018-12-12
    Sponsor Name:Department of Hematology, Herlev and Gentofte University Hospital
    Full Title: Phase IIa trial of PD-L1 peptide vaccination as monotherapy in high risk smoldering multiple myeloma
    Medical condition: High risk smoldering multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006253-41 Sponsor Protocol Number: DC-004 Start Date*: 2012-01-05
    Sponsor Name:The Norwegian Radium Hospital, Oslo University Hospital
    Full Title: Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanoma
    Medical condition: Malignant melanoma stage IV M1c or better
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002194-28 Sponsor Protocol Number: NL81713.078.22 Start Date*: 2023-03-20
    Sponsor Name:Erasmus MC
    Full Title: Phase I/II study to determine the safety, immunogenicity and efficacy of Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination (HEB-PEP-Study)
    Medical condition: HBeAg negative chronic HBV
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002951-14 Sponsor Protocol Number: 12/0357 Start Date*: 2016-06-17
    Sponsor Name:University College London
    Full Title: Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccinat...
    Medical condition: Anogenital warts
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059313 Anogenital warts PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018182 Genital warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000515-24 Sponsor Protocol Number: NL76470.078.21 Start Date*: 2021-02-15
    Sponsor Name:Erasmus University Medical Center
    Full Title: Vaccination Against Covid in Primary Immune Deficiencies
    Medical condition: Patients with primary immunodeficiency disease, also known as inborn errors pf immunity, are vaccinated against COVID-19 using COVID-19 Vaccine Moderna. The vaccine has been approved for use in the...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036700 Primary immunodeficiency syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008278-29 Sponsor Protocol Number: ABR16858METC08-342 Start Date*: 2009-07-20
    Sponsor Name:University Medical Center Utrecht
    Full Title: Is early revaccination after ALL therapy feasible ? Evaluation of loss of antibodies and responsiveness to (re)vaccination in children after treatment for acute lymphocytic leukemia
    Medical condition: To determine the effect of early (re) vaccination after acute lymphoblastic leukemia treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000850 Acute lymphoid leukemia in remission LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000934-38 Sponsor Protocol Number: CP-BR-1-2007 Start Date*: 2007-10-30
    Sponsor Name:Generex Biotechnology Corporation
    Full Title: Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vacci...
    Medical condition: Disease-free, conventionally treated node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002193-23 Sponsor Protocol Number: HLS04/2011 Start Date*: 2011-09-27
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled cli...
    Medical condition: HIV+ teenagers and young adults versus HIV-negative subjects: high-risk population for HPV-related disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 21:00:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA